Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ipsen Sa S/Adr (OP:IPSEY)

47.81 +1.66 (+3.61%)
Streaming Delayed Price Updated: 1:24 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 160
Open 47.81
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 46.15
Today's Range 47.81 - 47.81
52wk Range 25.11 - 47.81
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal ↗
In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. 
Via Talk Markets
Topics Initial Public Offering
News headline image
FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo ↗
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... 
Via Benzinga

Performance

YTD
+39.2%
+39.2%
1 Month
+17.0%
+17.0%
3 Month
+32.7%
+32.7%
6 Month
+44.2%
+44.2%
1 Year
+69.2%
+69.2%

More News

Read More
News headline image
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
3 Promising Biotech Stocks Flying Under the Radar ↗
Via InvestorPlace
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗
Via Benzinga
News headline image
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class ↗
Via Benzinga
News headline image
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients ↗
Via Benzinga
News headline image
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur ↗
Via Benzinga
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
From Ipsen
Via Business Wire
News headline image
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
From Ipsen
Via Business Wire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Why These Two Biotech Stocks Blasted Higher This Week ↗
Via The Motley Fool
News headline image
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday ↗
Via The Motley Fool
News headline image
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline ↗
Via Benzinga
News headline image
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
From Ipsen
Via Business Wire
News headline image
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
From Ipsen
Via Business Wire
News headline image
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗
Via Benzinga
News headline image
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
From Ipsen
Via Business Wire
News headline image
Why Merrimack Shares Are Surging Over 200% Today? ↗
Via Benzinga
News headline image
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
From Ipsen
Via Business Wire
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
Via Benzinga
News headline image
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
From Ipsen
Via Business Wire

Frequently Asked Questions

Is Ipsen Sa S/Adr publicly traded?
Yes, Ipsen Sa S/Adr is publicly traded.
What exchange does Ipsen Sa S/Adr trade on?
Ipsen Sa S/Adr trades on the OTC Traded
What is the ticker symbol for Ipsen Sa S/Adr?
The ticker symbol for Ipsen Sa S/Adr is IPSEY on the OTC Traded
What is the current price of Ipsen Sa S/Adr?
The current price of Ipsen Sa S/Adr is 47.81
When was Ipsen Sa S/Adr last traded?
The last trade of Ipsen Sa S/Adr was at 02/25/26 01:24 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.